HNB
HRTX icon

Huntington National Bank’s Heron Therapeutics HRTX Stock Holding History

Huntington National Bank’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-370
Closed -$566 – 4194
2024
Q4 		$566 Sell
370
-839
-69% -$1.36K ﹤0.01% 2479
2024
Q3 		$2.41K Buy
1,209
+478
+65% +$1.14K ﹤0.01% 2199
2024
Q2 		$2.56K Sell
731
-135
-16% -$415 ﹤0.01% 2098
2024
Q1 		$2.4K Buy
866
+496
+134% +$1.25K ﹤0.01% 2093
2023
Q4 		$629 Hold
370
– – ﹤0.01% 2277
2023
Q3 		$381 Hold
370
– – ﹤0.01% 2281
2023
Q2 		$429 Hold
370
– – ﹤0.01% 2237
2023
Q1 		$559 Hold
370
– – ﹤0.01% 2081
2022
Q4 		$925 Hold
370
– – ﹤0.01% 1856
2022
Q3 		$2K Hold
370
– – ﹤0.01% 1862
2022
Q2 		$1K Hold
370
– – ﹤0.01% 1963
2022
Q1 		$2K Hold
370
– – ﹤0.01% 1904
2021
Q4 		$3K Hold
370
– – ﹤0.01% 1820
2021
Q3 		$4K Hold
370
– – ﹤0.01% 1593
2021
Q2 		$6K Buy
+370
New +$5.89K ﹤0.01% 1532

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Huntington National Bank's HRTX Position: Q1 2025 in Review

Huntington National Bank sold out of Heron Therapeutics (HRTX) in Q1 2025, closing a stake of 370 shares — an estimated $566 sold.

Huntington National Bank first reported a position in HRTX in Q2 2021 and held it in 15 quarters. The position peaked at $6K in Q2 2021. 164 funds tracked by Wall St. Rank hold HRTX as of Q1 2025.

  • Huntington National Bank reported no remaining Heron Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Huntington National Bank sold 370 Heron Therapeutics shares in Q1 2025, an estimated $566.
  • Huntington National Bank first reported a position in Heron Therapeutics in Q2 2021 and held it in 15 quarters.
  • Huntington National Bank's Heron Therapeutics position peaked at $6K in Q2 2021.
  • 164 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2025.

Based on Huntington National Bank's 13F filing for Q1 2025, filed 14 May 2025.